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The flux of glucose entering the glycolytic pathway under various metabolic conditions has been indirectly monitored 
in the Langendorff perfused rat heart using 31P-NMR spectroscopy. By totally inhibiting (> 95%) glyceraldehyde-3-phos- 
phate dehydrogenase with low concentrations of iodoacetic acid (0.2 mM) in the perfusion medium, active glycolysis 
results in the accumulation of sugar phosphate species (fructose 1,6_bisphosphate, dihydroxyacetone phosphate, and gly- 
ceraldehyde 3-phosphate) which can be observed in the slP-NMR spectrum. Using this technique, it has been shown 
that butyrate (10 mM) in the perfusion medium decreases the flux through the initial steps of the glycolytic pathway 
by at least 6-fold and that both glucose phosphorylation and glycogenolysis are inhibited. Upon total global ischemia 
in the presence of both glucose and butyrate, the glycolysis rate is stimulated approx. lOO-fold. 
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1. INTRODUCTION 
The availability of fatty acids as an alternative 
energy source for the glucose-perfused rat heart 
has been shown to inhibit significantly the utiliza- 
tion of glucose [l-4]. Although the exact 
mechanism by which the presence of fatty acids in- 
hibits glucose utilization is somewhat uncertain, 
the observed accumulation of glucose [3] in the 
heart when both glucose and fatty acids are provid- 
ed in the medium suggests that the inhibition of 
glucose utilization occurs after glucose uptake but 
before the first phosphorylation event. “P-NMR 
spectroscopy of the Langendorff perfused rat 
heart can be used to follow changes in the concen- 
trations of major pools of phosphorus-containing 
metabolites in vivo [5]. However, the normally low 
steady-state concentrations of the phosphorus- 
containing intermediates of glycolysis generally 
preclude their direct detection by “P-NMR spec- 
troscopy. By totally (> 95%) inhibiting glycolysis 
at the level of glyceraldehyde3-phosphate 
dehydrogenase by perfusion with iodoacetic acid 
(0.2 mM) [6], it is possible to observe the flux 
through the initial steps of glycolysis as an ac- 
cumulation of an equilibrium mixture of fructose 
1,6-bisphosphate, glyceraldehyde 3-phosphate and 
dihydroxyacetone phosphate (Chatham, J.C., 
Gilbert, H.F. and Radda, G.K., unpublished) 
which gives rise to signals in the “P-NMR spec- 
trum. Using this technique it has been shown that 
the presence of butyrate in the perfusion medium 
significantly inhibits glycolysis and glycogenolysis 
and that upon total global ischemia, glycolysis is 
greatly stimulated without a significant alteration 
in intracellular pH because lactate production is in- 
hibited under these conditions. 
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buffer was continually equilibrated with 95% Oz/5% COz to 
maintain a pH of 7.4. All chemicals were of analytical grade. 
Sodium butyrate when present was added at 10 mM, and the 
NaCl concentration decreased to maintain constant sodium 
concentration. Glucose when present was at 11 mM. Iodoacetic 
acid (sodium salt) adjusted to pH 7.4 (10 mM) was added to the 
perfusion line by a peristaltic pump with the flow rate adjusted 
so that the final concentration of iodoacetate in the perfusate 
was 0.2 mM. 
The activity of glyceraldehyde-3-phosphate dehydrogenase 
was assayed according to [8] after homogenizing heart tissue in 
9 vols triethanolamine buffer (0.1 M, pH 7.5) containing 1 mM 
EDTA and 5 mM MgS04. “P-NMR spectra were collected on 
hearts perfused as described above by using a 4.2 T vertical 
wide-bore superconducting magnet interfaced with a Nicolet 
1180 spectrometer. Spectra were collected in 5-min blocks (256 
scans, 70” pulse width). Peak intensities were determined 
relative to the signal from a methylene diphosphonate (MDP) 
standard contained in a capillary in the sample chamber. 
Calibration of the total sugar phosphate concentration in in- 
dividual perfused hearts was accomplished by relating the 
heights of the observed sugar phosphate peak (relative to the 
height of the internal MDP standard) to the level of fructose 
1,6-bisphosphate plus dihydroxyacetone phosphate and 
glyceraldehyde 3-phosphate determined by enzymatic methods 
in acid extracts of heart homogenates. Fructose 
1,6-bisphosphate in neutralized acid extracts of heart tissue was 
determined by measuring the decrease in absorbance at 340 nm 
due to NADH oxidation in the presence of 5 U/ml of aldolase 
and glycerol-3-phosphate dehydrogenase. The sum of 
glyceraldehyde 3-phosphate and dihydroxyacetone phosphate 
was evaluated by observing the decrease in absorbance at 
340 nm due to NADH oxidation in the presence of 5 U/ml 
triosephosphate isomerase and glycerol-3-phosphate 
dehydrogenase. One arbitrary unit of sugar phosphate peak 
height relative to the external MDP standard shown in fig.2 cor- 
responds to a concentration of fructose 1,6-bisphosphate plus 
triose phosphates of 3.7 f 0.3 pmol/g tissue per peak height 
unit (average of duplicate determinations). Glucose 
6-phosphate plus fructose 6-phosphate represented less than 
20% of the sugar phosphate pool. 
3. RESULTS AND DISCUSSION 
31P-NMR spectroscopy of intact tissue has been 
used to monitor the changes in major phosphorus- 
containing metabolites, to determine the in- 
tracellular pH, and to estimate the concentration 
of free ADP under a variety of metabolic condi- 
tions [5]. The utility of 31P-NMR for the in vivo 
determination of the concentrations of phosphorus 
metabolites is restricted by the inherent insensitivi- 
ty of the technique. Generally, only the most abun- 
dant phosphorus-containing metabolites are 
observed. In the normal perfused rat heart, “P- 
NMR signals are observed for only ATP, 
phosphocreatine and inorganic phosphate. Inter- 
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conversions of these abundant metabolites can be 
examined in vivo in a non-destructive, non- 
invasive manner. However, it is generally impossi- 
ble to observe the presence of a very large number 
of phosphorus metabolites of lower concentration 
(< 1 mM). ADP concentrations can be inferred 
from the equilibrium position of creatine kinase, 
but the phosphorus-containing intermediates of 
glycolysis cannot normally be detected. In the 
presence of a specific inhibitor, however, the nor- 
mally invisible intermediates of glycolysis will ac- 
cumulate behind the inhibited step. The 
accumulation of these normally invisible in- 
termediates can then be used to estimate the flux 
through glycolysis. Thus, metabolic inhibitors can 
be used to extend the utility of 31P-NMR methods. 
The addition of 0.2 mM iodoacetate to normal 
Krebs-Henseleit buffer containing 11 mM glucose 
results in a very rapid disappearance of ATP and 
phosphocreatine signals with the concurrent ap- 
pearance of new resonances in the sugar phosphate 
region of the spectrum (figs 1,2) and irreversible 
loss of cardiac function. Assay of phosphorus- 
containing metabolites from homogenates of 
rapidly frozen tissue after perfusion with 
iodoacetate showed a significant increase in the 
levels of fructose 1,6-bisphosphate, glyceraldehyde 
3-phosphate and dihydroxyacetone phosphate (not 
shown), similar to the increase observed upon in- 
hibition of glyceraldehyde-3-phosphate d hydro- 
genase by perfusion with hydrogen peroxide 
(Chatham, J.C., Gilbert, H.F. and Radda, G.K., 
unpublished). Assays of enzyme activity showed 
that hexokinase, phosphofructokinase and 
pyruvate kinase activities of the iodoacetate- 
treated hearts were normal but that the activity of 
glyceraldehyde-3-phosphate dehydrogenase was 
>95% inhibited (not shown). 
The rate of accumulation of sugar phosphate 
resonances (fig.2) is comparable to the expected 
rate of glycolysis (table 1); however, the rate of 
sugar phosphate accumulation after adding iodo- 
acetate to the perfusion may also reflect the rate of 
inactivation of glyceraldehyde-phosphate de- 
hydrogenase, rather than providing a true measure 
of the actual rate of glycolysis during the initial 
perfusion. 
The inclusion of butyrate, an alternative sub- 
strate for oxidative phosphorylation which does 
not rely on glycolysis for metabolism, protects 
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Fig.1. Typical “P-NMR spectra of the Langendorff perfused rat heart under various conditions. (A) Control heart perfused for 30 min 
with 11 mM glucose in the absence of iodoacetate or butyrate. (B) Heart perfused for 30 min with 11 mM glucose and 0.2 mM 
iodoacetate. (C) Heart perfused for 35 min with 11 mM glucose, 0.2 mM iodoacetate, and 10 mM butyrate. (D) Heart perfused for 
20 min as in (C) and then subjected to 10 min of total global &hernia. Peak identification: MDP, methylene diphoshonate; SP, sugar 
phosphates; Pi, inorganic phosphate; CrP, creatine phosphate; ATP, cr-, ,& and y-phosphates. 
against the effects of iodoacetate with only small 
losses in ATP or phosphocreatine and no decrease 
in function for up to 1 h (figs 1,2). Assays of 
glyceraldehyde-3-phosphate d hydrogenase activi- 
ty in heart homogenates perfused with butyrate, 
glucose, and iodoacetate show c 5% of the normal 
activity of the enzyme. Although the enzyme is 
completely inhibited, there is no significant ac- 
cumulation of sugar phosphate in the heart when 
butyrate is present (fig.2, table 1). Phosphoryla- 
tion of glucose can occur in both the presence and 
absence of iodoacetate; however, in the presence 
of iodoacetate, a significant flux through the initial 
stages of glycolysis would result in the accumula- 
tion of fructose 1,6-bisphosphate and triose 
phosphates, since glyceraldehyde-3-phosphate 
dehydrogenase is inhibited. In the presence of 
iodoacetate, the sugar phosphates which ac- 
cumulate are predominately (> 80%) fructose 
1,6-bisphosphate and the triose phosphates. In the 
presence of iodoacetate and butyrate, the slow ap- 
pearance of sugar phosphate signals in the NMR 
spectrum suggests that butyrate in the perfusion 
medium produces at least a 6-fold reduction in the 
rate of glycolysis. If the inhibition of glycolysis by 
butyrate occurred after the initial phosphorylation 
of glucose by hexokinase but before the glyceral- 
dehyde-3-phosphate dehydrogenase step, other 
sugar phosphates (such as glucose 6-phosphate, 
glucose l-phosphate, or fructose 6-phosphate) 
447 
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Fig.2. Time courses of the accumulation of sugar phosphate 
resonances. (0) Perfusion with 11 mM glucose and 0.2 mM 
iodoacetate; (=) perfusion with 11 mM glucose, 0.2 mM 
iodoacetate and 10 mM butyrate; (A) perfusion with 11 mM 
glucose, 0.2 mM iodoacetate and 10 mM butyrate for 20 min 
followed by total global ischemia at time zero. All peak heights 
have been normalized to the MDP standard and are the average 
of at least three individual experiments. Error bars indicate 
+ 1 SD. 
would be expected to accumulate at the normal 
rate. Since this is not observed, the inhibition of 
glycolysis by butyrate likely occurs before phos- 
phorylation of glucose. These observations are in 
agreement with previous studies showing a 
decrease in the rate of glycolysis [1,2,4] and ac- 
cumulation of free intracellular glucose [3] in the 
presence of butyrate. The results also suggest hat 
the effects of iodoacetate on high-energy phos- 
phate metabolism are reasonably specific. 
If hearts perfused with iodoacetate, glucose and 
butyrate are subjected to a period of total global 
ischemia, there is a very rapid accumulation of 
sugar phosphate and ‘a correspondingly rapid loss 
of function (figs 1,2). The rate of sugar phosphate 
accumulation upon total global ischemia is ac- 
celerated lOO-fold compared to the normoxic rate 
in the presence of butyrate (table l), and ap- 
proaches a rate comparable to the rate of glycolysis 
during anoxia as measured by others (table 1). 
The rapid accumulation of sugar phosphate as a 
consequence of total global ischemia is not accom- 
panied by a significant change in intracellular pH. 
Table 1 
Rates of glycolysis in the Langendorff perfused rat heart under 
various metabolic conditions 
Additions Glycolysis rate Reference 
No additions 
11.5 mM glucose 0.54 4 
5.5 mM glucose + insulin 
(1 mu/ml) 1.3 2 
5.5 mM glucose + insulin + 
4 mM butyrate 0.66 2 
10 mM glucose + anoxia 4.1 9 
Iodoacetate (0.2 mM) 
11.5 mM glucose 0.34 + 0.07 this study 
11.5 mM glucose + 4 mM 
butyrate 0.05 + 0.005 this study 
11.5 mM glucose + 4 mM 
butyrate + total global 
ischemia 26 this study 
All hearts were perfused at 37°C with Krebs-Henseleit buffer 
containing the additions listed. Glycolysis rates are reported in 
units of rmol glucose/min per g wet wt heart tissue. Rate 
measurements are based on the curves shown in fig.2. Errors 
given encompass the range of values consistent with error in the 
individual time points 
pH values measured by NMR [5] were 7.03 and 
6.91 before and after ischemia, respectively. The 
lack of a significant pH drop in response to signifi- 
cant acceleration of glycolysis is also consistent 
with the inhibition of lactate formation caused by 
inhibition of glycolysis at the glyceraldehyde-3- 
phosphate dehydrogenase step. 
In summary, 31P-NMR of the perfused rat heart 
has confirmed the inhibition of glucose 
phosphorylation in vivo by the presence of fatty 
acids in the perfusion medium. The acceleration of 
glycolysis during ischemia has also been shown to 
occur in the absence of a significant change in in- 
tracellular pH. The use of specific metabolic in- 
hibitors provides a useful supplement to “P-NMR 
studies of metabolism in vivo. 
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